Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075
نویسندگان
چکیده
منابع مشابه
Single Orbital Metastasis in Castration-Resistant Prostate Cancer
Introduction: Orbital metastasis of prostate cancer (PC) is very rare and even more unique in castration-resistant PC (CRPC). In this scenario, choline positron emission tomography/computed tomography (choline PET/CT) is the gold-standard restaging method of choice available in our setting, and new anti-androgens treatments show improvement in overall survival. Case presentation: We report the...
متن کاملSingle Orbital Metastasis in Castration-Resistant Prostate Cancer
Introduction: Orbital metastasis of prostate cancer (PC) is very rare and even more unique in castration-resistant PC (CRPC). In this scenario, choline positron emission tomography/computed tomography (choline PET/CT) is the gold-standard restaging method of choice available in our setting, and new anti-androgens treatments show improvement in overall survival. Case presentation: We report the...
متن کاملCastration-resistant Prostate CanCer
• Objective: To review therapeutics for castrationresistant prostate cancer (CRPC). • Methods: Literature review. • Results: Targeting of androgen-dependent pathways in CRPC post-chemotherapy has been shown to improve survival with the lyase inhibitor abiraterone and lead to PSA and objective responses with an androgen receptor antagonist (MDV3100). However, the addition of bevacizumab to docet...
متن کاملNonmetastatic Castration-Resistant Prostate Cancer
After the introduction of prostate cancer screening with the prostate-specific antigen (PSA) test, we have witnessed a dramatic stage migration. As a result, an increasing number of patients are diagnosed at earlier stages and receive local treatments including surgery or radiation. When these local treatments fail by the definition of increasing PSA levels, patients are usually treated with an...
متن کاملNovel hormonal therapy for castration-resistant prostate cancer.
Prostate cancer is the most common cancer in European men and the second leading cause of death [1]. For patients who relapse after treatment of organ-confined disease or those who have initial metastatic disease, testosterone suppression is the mainstay of therapy. Manipulating the androgen receptor (AR) axis was the first method discovered, which could actively control prostate cancer. In fac...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Molecular Cancer Research
سال: 2016
ISSN: 1541-7786,1557-3125
DOI: 10.1158/1541-7786.mcr-16-0221